K. Harrap

发表

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.

A. Jackman, T. Stephens, M. Azab, 1995, European journal of cancer.

The integrity of nuclear proteins following incubation of isolated nuclei in vitro.

D. Rickwood, S. Sellwood, K. Harrap, 1975, European journal of biochemistry.

The interaction of bifunctional alkylating agents with the DNA of tumour cells.

K. Harrap, E. Gascoigne, 1976, European journal of cancer.

Computer models of anticancer drug interaction.

R. Jackson, K. Harrap, 1979, Pharmacology & therapeutics.

Towards selectivity in cancer chemotherapy: a biochemical overview.

K. Harrap, 1978, Advances in enzyme regulation.

Non-surgical aspects of ovarian cancer Report of a Meeting of Physicians and Scientists, Institute of Cancer Research and the Royal Marsden Hospital, London

M. Gore, I. Jacobs, C. Fisher, 1994, The Lancet.

Determination of metabolites of a novel platinum anticancer drug JM216 in human plasma ultrafiltrates.

F. Raynaud, B. Murrer, P. Mistry, 1995, Journal of pharmaceutical and biomedical analysis.

Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery

L. Kèlland, M. Valenti, G. Abel, 2004, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function.

Z. Siddik, D. Newell, S. Harland, 1984, Cancer research.

Selection of potential second generation platinum compounds

Michael G. K. Jones, P. Cox, K. Harrap, 1978 .

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.

I. Judson, L. Kèlland, F. Raynaud, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cisplatin induces apoptosis in a human ovarian carcinoma cell line without concomitant internucleosomal degradation of DNA.

C. O'Neill, M. Ormerod, K. Harrap, 1994, Experimental cell research.

A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration

I. Judson, C. O'Neill, L. Kèlland, 2004, Cancer Chemotherapy and Pharmacology.

Dinucleotide analogues as inhibitors of thymidine kinase, thymidylate kinase, and ribonucleotide reductase.

L. Davies, K. Harrap, S. E. Barrie, 1988, Journal of medicinal chemistry.

Ammine/Amine Platinum IV Dicarboxylates: A Novel Class of Complexes Which Circumvent Intrinsic Cisplatin Resistance

L. Kèlland, C. Giandomenico, B. Murrer, 1991 .

Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors.

S. Clarke, J. Verweij, I. Judson, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TomudexTM (ZD1694): from concept to care, a programme in rational drug discovery

A. Jackman, K. Harrap, F. T. Boyle, 2004, Investigational New Drugs.

Preclinical studies identifying carboplatin as a viable cisplatin alternative.

K. Harrap, 1985, Cancer treatment reviews.

SITES OF ACTION OF AMETHOPTERIN: INTRINSIC AND ACQUIRED DRUG RESISTANCE *

B. Hill, K. Harrap, L. Hart, 1971, Annals of the New York Academy of Sciences.

Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian‐carcinoma cell lines

L. Kèlland, P. Mistry, K. Harrap, 1993, International journal of cancer.

Biotransformation of the platinum drug JM216 following oral administration to cancer patients

L. Kèlland, F. Raynaud, B. Murrer, 1996, Cancer Chemotherapy and Pharmacology.

Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.

L. Kèlland, B. Murrer, G. Abel, 1992, Cancer research.

ANTITUMOR, TOXIC AND BIOCHEMICAL PROPERTIES OF CISPLATIN AND EIGHT OTHER PLATINUM COMPLEXES

K. Harrap, C. R. Wilkinson, H. Clink, 1980 .

Initiatives with platinum- and quinazoline-based antitumor molecules--Fourteenth Bruce F. Cain Memorial Award Lecture.

K. Harrap, 1995, Cancer research.

Quantitative high-performance liquid chromatography of nucleosides and bases in human plasma.

K. Harrap, G. Taylor, P. Dady, 1980, Journal of chromatography.

Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.

R. Shepherd, K. Harrap, 1982, British Journal of Cancer.

The cytotoxicity of chlorambucil and its associated effects on NAD metabolism.

K. Harrap, M. Furness, 1973, European journal of cancer.

The Clinical Development of the Oral Platinum Anticancer Agent JM216

I. Judson, F. Raynaud, B. Murrer, 1996 .

The clinical pharmacology of the adenosine deaminase inhibitor 2′-deoxycoformycin

R. Adamson, J. Smyth, A. Jackman, 2004, Cancer Chemotherapy and Pharmacology.

Biochemical consequences of treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.

J. Smyth, K. Harrap, R. Paine, 1979, Advances in experimental medicine and biology.

Adenosine metabolism in cultured lymphoid cells.

K. Harrap, R. Paine, 1976, Advances in enzyme regulation.

The occurrence of protein-bound mixed disulfides in rat tissues.

C. Smith, R. Jackson, B. Hill, 1973, Biochimica et biophysica acta.

The effect of the nucleoside transport inhibitor dipyridamole on the incorporation of [3H]thymidine in the rat.

P. O'Connor, D. Newell, A. Calvert, 1986, Biochemical pharmacology.

Studies on the mechanism of action of LS 1727, a nitrosocarbamate of 19-nortestosterone.

S. Venitt, K. Harrap, B. Hartley‐åsp, 2009, Acta pharmacologica et toxicologica.

Studies on the toxicity and antitumour activity of prednimustine, a prednisolone ester of chlorambucil.

S. Sellwood, K. Harrap, P. Riches, 1977, European journal of cancer.

The binding of [3H]chlorambucil to nuclear proteins of the Yoshida ascites sarcoma.

K. Harrap, P. Riches, 1975, Chemico-biological interactions.

Criteria for the selection of second-generation platinum compounds.

R. Shepherd, K. Harrap, H. Kuśnierczyk, 1980, British Journal of Cancer.

Discovery of Improved Platinum Analogues

K. Harrap, 1994 .

Adenosine deaminase activity in leukaemia.

J. Smyth, K. Harrap, 1975, British Journal of Cancer.

Future possibilities for the development of treatments of leukemia.

K. Harrap, F. Bergel, 1965, Cancer research.

Thymidylate synthase: a target for anticancer drug design.

D. Newell, A. Jackman, A. Calvert, 1989, Advances in enzyme regulation.

Some biochemical aspects of leukaemias: Leucocyte glutathione metabolism in chronic granulocytic leukaemia.

R. Jackson, K. Harrap, 1969, European journal of cancer.

Some aspects of sulphydryl metabolism in granulocytic leukaemia.

K. Harrap, 1965, European journal of cancer.

A Model System for Cysteine Desulphydrase Action: Pyridoxal Phosphate–Vanadium

R. Bray, K. Harrap, F. Bergel, 1958, Nature.

Synthesis and antiviral activity of some new S-adenosyl-L-homocysteine derivatives.

E. De Clercq, J. Balzarini, K. Harrap, 1992, Journal of medicinal chemistry.

Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel Trans platinum complex, JM335 [Trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)]

L. Kèlland, K. Harrap, K. Mellish, 1994, International journal of cancer.

A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice.

A. Jackman, A. Calvert, S. Brown, 1981, European journal of cancer.

Quinazoline antifolates inhibiting thymidylate synthase: variation of the amino acid.

L. Davies, A. Jackman, A. Calvert, 1986, Journal of medicinal chemistry.

Quinazoline antifolates inhibiting thymidylate synthase: benzoyl ring modifications.

A. Jackman, S. Harland, A. Calvert, 1986, Journal of medicinal chemistry.

Some Biochemical Aspects of Leukaemias: The Appearance of a Soluble Disulphide in the Blood in Chronic Granulocytic Leukaemia

D. Speed, K. Harrap, 1964, British Journal of Cancer.

In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.

L. Kèlland, K. Harrap, K. Mellish, 1993, British Journal of Cancer.

Platinum Analogues: Criteria for Selection

K. Harrap, 1983 .

Historical aspects of glutathione and cancer chemotherapy.

P. Mistry, K. Harrap, 1991, Pharmacology & therapeutics.

Methotrexate or 5-Fluorouracil Mouse 5178 Y Lymphoma Cells following Exposure to Changes in the Deoxyribonucleoside Triphosphate Pools of Updated Version

M. Tattersall, K. Harrap, 2006 .

Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120

M. Walton, L. Kèlland, D. Thurston, 1996, Cancer Chemotherapy and Pharmacology.

Enhancement of rat liver uridine kinase activity by various metabolic inhibitors.

K. Harrap, J. Veselý, A. Čihák, 1974, Biochemical pharmacology.

Effects of thymidine (tdr) and/or purines on the reversibility of methotrexate (mtx) toxicity in mice. Abstr.

D. Talbot, K. Harrap, J. Straw, 1976 .

Factors determining cell sensitivity to methotrexate: studies of folate and deoxyribonucleoside triphosphate pools in five mammalian cell lines.

M. Tattersall, R. Jackson, K. Harrap, 1974, European journal of cancer.

Intrinsic resistance to methotrexate of cultured mammalian cells in relation to the inhibition kinetics of their dihydrololate reductases.

R. Jackson, K. Harrap, L. Hart, 1976, Cancer research.

Inhibition of human leukaemic thymidylate kinase and L1210 ribonucleotide reductase by dinucleotides of adenosine and thymidine and their phosphonate analogues.

L. Davies, R. Powles, G. A. Taylor, 1988, Biochemical pharmacology.

New Avenues in Developmental Cancer Chemotherapy

T. A. Connors, Kenneth R. Harrap, Thomas A. Connors, 1987 .

Cytosine arabinoside uptake by tumour cells in vitro.

J. Mulder, K. Harrap, 1975, European journal of cancer.

Enzyme kinetics and combination chemotherapy: an appraisal of current concepts.

R. Jackson, K. Harrap, 1975, Advances in enzyme regulation.

Studies with a mathematical model of folate metabolism.

R. Jackson, K. Harrap, 1973, Archives of biochemistry and biophysics.

Enhancement of the therapeutic effectiveness of methotrexate and protection of normal proliferating tissues with purines and pyrimidines.

G. Browman, K. Harrap, G. A. Taylor, 1977, Chemico-biological interactions.

Some observations on the reversibility of methotrexate toxicity in normal proliferating tissues.

D. Talbot, K. Harrap, J. Straw, 1977, Journal of the National Cancer Institute.

Combination chemotherapy: the interaction of methotrexate and 5-fluorouracil.

T. A. Connors, M. Tattersall, R. Jackson, 1973, European journal of cancer.

Combination chemotherapy: the antagonism of methotrexate and cytosine arabinoside.

M. Tattersall, K. Harrap, 1973, European journal of cancer.

Interaction of methotrexate and cytosine arabinoside.

T. A. Connors, M. Tattersall, K. Harrap, 1972, Lancet.

Aspects of the biochemical pharmacology of cytembena.

R. Jackson, K. Harrap, G. A. Taylor, 1975, Neoplasma.

The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.

M. Valenti, P. Goddard, K. Harrap, 1991, Annals of oncology : official journal of the European Society for Medical Oncology.

Genomic imbalances associated with acquired resistance to platinum analogues.

B. Leyland-Jones, L. Kèlland, L. Hiorns, 1999, The American journal of pathology.

Studies on the pharmacokinetics of chlorambucil and prednimustine in man.

D. Newell, A. Calvert, T. Mcelwain, 1983, British journal of clinical pharmacology.

Combination Chemotherapy: The Interaction of Methotrexate and

T. A. Connors, R. Jackson, K. Harrap, 1973 .

The clinical pharmacology of chlorambucil and prednimustine.

D. Newell, A. Calvert, T. Mcelwain, 1983, British journal of clinical pharmacology.

Estimation of chlorambucil, phenyl acetic mustard and prednimustine in human plasma by high-performance liquid chromatography.

D. Newell, K. Harrap, L. Hart, 1979, Journal of chromatography.

cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines

C. O'Neill, L. Kèlland, M. Ormerod, 2009, Cancer Chemotherapy and Pharmacology.

Some effects of chlorambucil on nuclear protein phosphorylation in the Yoshida ascites sarcoma.

S. Sellwood, K. Harrap, P. Riches, 1977, Chemico-biological interactions.

Some effects of chlorambucil on the chromatin of Yoshida ascites sarcoma cells.

K. Harrap, P. Riches, 1973, Cancer research.

Enhancement of the nuclear reactivity of alkylating agents by prednisolone.

K. Harrap, M. Birbeck, R. Wilkinson, 1979, Cancer research.

The binding of (3H)chlorambucil to isolated nuclear proteins of the Yoshida ascites sarcoma.

S. Sellwood, K. Harrap, P. Riches, 1975, Biochemical Society transactions.

Phosphorylation of Nuclear Proteins in Rodent Tissues

D. Rickwood, S. Sellwood, K. Harrap, 1973 .

Some effects of chlorambucil on the uptake and utilization of sulphydryl-containing compounds by tumour cells.

C. Smith, R. Jackson, K. Harrap, 1973, Biochemical pharmacology.

Binding of glutathione and cysteine to cellular protein by mixed disulphide bonds.

C. Smith, R. Jackson, K. Harrap, 1968, The Biochemical journal.

Deoxyribonucleoside triphosphate pools and adenosine toxicity.

J. Smyth, K. Harrap, 1977, Biochemical pharmacology.

Some effects of chlorambucil on enzymes of glutathione metabolism in drug-sensitive and -resistant strains of the Yoshida ascites sarcoma.

R. Jackson, B. Hill, K. Harrap, 1969, The Biochemical journal.

Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.

L. Kèlland, G. Abel, P. Mistry, 1992, British Journal of Cancer.

The comparative tissues distribution of platinum and 14C in mice receiving 14C-labelled carboplatin

Z. Siddik, K. Harrap, S. Dible, 1988, Cancer Chemotherapy and Pharmacology.

Comparative distribution and excretion of carboplatin and cisplatin in mice

Z. Siddik, F. Boxall, K. Harrap, 1988, Cancer Chemotherapy and Pharmacology.

Pharmacokinetics of c / s-Diammine-1 , 1-cyclobutane Dicarboxylate Platinum ( ll ) in Patients with Normal and Impaired Renal Function 1

Z. Siddik, D. Newell, S. Harland, 2006 .

789. Interaction between carbonyl groups and biologically essential substituents. Part III. The formation of a thiazolidine derivative in aqueous solution from pyridoxal phosphate and L-cysteine

K. Harrap, F. Bergel, 1961 .

The Uptake and Utilization of Chlorambucil by Lymphocytes from Patients with Chronic Lymphocytic Leukaemia

B. Hill, K. Harrap, 1972, British Journal of Cancer.

20 – Drug Resistance as a Focus for New Drug Design

Z. Siddik, P. Goddard, K. Harrap, 1988 .

Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.

L. Kèlland, F. Raynaud, B. Murrer, 1995, Journal of chromatography. A.

The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor.

L. Brunton, A. Jackman, R. Kimbell, 1994, Advances in experimental medicine and biology.

Antimetabolites in cancer chemotherapy.

S. Clarke, A. Jackman, K. Harrap, 1991, Advances in experimental medicine and biology.

The effects of chlorambucil on the utilization of exogenous thymidine by tumour cells.

K. Harrap, P. Riches, E. Gascoigne, 1975, Biochemical pharmacology.

The comparative pharmacokinetics of pentamethylmelamine in man, rat, and mouse

D. Newell, K. Harrap, J. Muindi, 1982, Cancer Chemotherapy and Pharmacology.

A prednisolone ester of chlorambucil.

S. Sellwood, K. Harrap, P. Riches, 1977 .

Synthesis and Reactions of a New Class of Orally Active Pt(IV) Antitumor Complexes

L. Kèlland, C. Giandomenico, M. Abrams, 1991 .

The clinical pharmacokinetics of the novel antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717)

D. Newell, A. Calvert, S. Harland, 2004, Cancer Chemotherapy and Pharmacology.

Biochemical mechanisms of resistance to antimetabolites.

R. Jackson, K. Harrap, 1978, Antibiotics and chemotherapy.

The application of 5,5' dithiobis-2-nitrobenzoic acid to the determination of the acid-soluble disulphide content of blood.

K. Harrap, 1967, Biochemical pharmacology.

Establishment and Characterization of an in Vitro Model of Acquired Resistance to Cisplatin in a Human Testicular Nonseminomatous Germ Cell Line1

J. J. Roberts, L. Kèlland, G. Abel, 2006 .

The 5-HT3 antagonist, BRL 43694, does not compromise the efficacy of cisplatin in tumour-bearing mice

M. Valenti, P. Goddard, K. Harrap, 2004, Cancer Chemotherapy and Pharmacology.

A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.

L. Kèlland, M. Valenti, B. Murrer, 1994, Cancer research.

(jm221) in Human Ovarian Carcinoma Cell Lines Amminedibutyratodichloro(cyclohexylamine)platinum(iv) Cisplatin with That of Tetraplatin and Comparison of Cellular Accumulation and Cytotoxicity of Updated Version Citing Articles E-mail Alerts Comparison of Cellular Accumulation and Cytotoxicity of Cis

L. Kèlland, B. Murrer, G. Abel, 2022 .

The Non-Random Binding of Chlorambucil to DNA in Chromatin

K. Harrap, R. M. Orr, A. Jeney, 1984 .

205. Interaction between carbonyl groups and biologically essential substituents. Part IV. An enzyme model system for cysteine desulphydrase

K. Harrap, A. Scott, F. Bergel, 1962 .

Studies on the Mechanism of CB 3717 Induced Hepatotoxicity

A. Calvert, K. Harrap, N. Dr, 1984 .

A potent quinazoline inhibitor of thymidylate synthetase (ts) possessing significant antitumour activity in animals. Abstr.

A. Jackman, A. Calvert, K. Harrap, 1980 .

In vivo inhibition of mouse liver methyltransferase enzymes following treatment with 2'-deoxycoformycin and 2'-deoxyadenosine.

J. Renshaw, K. Harrap, 1986, Advances in experimental medicine and biology.

Changes in the deoxyribonucleoside triphosphate pools of mouse 5178Y lymphoma cells following exposure to methotrexate or 5-fluorouracil.

M. Tattersall, K. Harrap, 1973, Cancer research.

2'-Deoxycytidine kinase deficiency is a major determinant of 2-chloro-2'-deoxyadenosine resistance in lymphoid cell lines

D. Talbot, G. Aherne, Orr, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.

L. Kèlland, J. Roberts, G. Abel, 1992, Cancer research.

Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.

L. Kèlland, M. Valenti, B. Murrer, 1993, Cancer research.